Altretamine for the treatment of metastatic renal cell carcinoma - A Hoosier Oncology Group trial

Authors
Zon, RT McClean, J Helman, D Ansari, R Picus, J Sandler, A Williams, SD Loehrer, PJ
Citation
Rt. Zon et al., Altretamine for the treatment of metastatic renal cell carcinoma - A Hoosier Oncology Group trial, INV NEW DR, 19(3), 2001, pp. 229-231
Citations number
7
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
INVESTIGATIONAL NEW DRUGS
ISSN journal
01676997 → ACNP
Volume
19
Issue
3
Year of publication
2001
Pages
229 - 231
Database
ISI
SICI code
0167-6997(2001)19:3<229:AFTTOM>2.0.ZU;2-9
Abstract
Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m(2) days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experi enced Grade 3 gait abnormalities. None of the thirty evaluable patients ach ieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.